Background: Small-cell lung cancer (SCLC) carries the worst prognosis among lung cancer diagnoses. Combined radiation and chemotherapy is the standard of care; however, treatment outcomes vary. Variability in the rate at which chemotherapy agents are metabolized and in the capacity of repairing DNA damage has been hypothesized to be partly responsible for the treatment response variation. Genes in the glutathione metabolism and DNA repair pathways were tested through tag single-nucleotide polymorphisms (SNPs) to assess their association with survival in SCLC.
introduction Small-cell lung cancer (SCLC) is the most aggressive cell type among lung cancer subtypes; median survival following diagnosis is estimated to be 8-20 months [1, 2] . Virtually all patients with SCLC are treated with chemotherapy and/or radiation therapy; platinum-containing compounds (cisplatin and carboplatin) are most commonly used, and patient survival varies substantially. Platinum chemotherapeutic compounds exert their cytotoxic effects by covalently binding DNA purine bases and forming adducts, and when in cells, these compounds go through various biological transformation processes for either detoxification or excretion. Two pathways involved in platinum-based drug metabolism and treatment efficacy are phase II drug conjugation by glutathione and DNA repair system. The glutathione pathway includes enzymes responsible for glutathione synthesis, redox, glutathione conjugation, and transportation that remove glutathione conjugates from cells as reviewed previously [3] . High activity of the glutathione pathway may accelerate the excretion and reduce the concentration of platinum agents in cells. Deletion or single-nucleotide polymorphisms (SNPs) of genes in this pathway have been linked to varied clinical outcomes in non-small-cell lung cancer (NSCLC) [4] [5] [6] [7] [8] [9] [10] . Furthermore, the cytotoxic effect of platinum compounds on a DNA molecule can be reversed by the DNA repair mechanism consisting of several pathways and a network of many proteins. Nucleotide excision repair (NER) is one of the main mechanisms responsible for drug resistance by increased platinum-DNA adduct removal, and high levels of ERCC1 or XPD activity, for example, are associated with resistance to platinum compounds and patient survival [11, 12] .
Although many studies have demonstrated significant genetic associations between genomic variations of the genes participating in the metabolism of platinum-based drugs and original article patients and methods
subjects
The participants in the study were SCLC patients, diagnosed at Mayo Clinic from 1997 to 2007 who consented to the research protocol as approved by institutional review board and donated their blood. Detailed description of identification, enrollment, blood collection, and follow-up has been provided previously [17, 18] . Briefly, each case was identified through the Mayo Clinic pathologic diagnostic system, their medical records were abstracted, and blood samples were collected. Tumor stage was defined as limited stage (involving one lung or with lymph node involvement on the same side of the chest) and extensive stage, where cancer had spread to the other lung, to lymph nodes on the other side of the chest, or to distant organs. Smoking information was obtained from medical record abstraction, questionnaires, and/or patient interviews. Pack-years were calculated by multiplying the number of packs per day by the total years of smoking. Never smokers were defined as having had smoked <100 cigarettes during their lifetime, and former smokers were defined as having had at least 6 months of smoking abstinence at the time of diagnosis. Vital status and cause of death were determined by reviewing the Mayo Clinic registration database and medical records, correspondence from patients' next of kin, death certificates, obituary documents, the Mayo Clinic Tumor Registry, and the Social Security Death Index Web site. Additional patient information was collected with a mail-in questionnaire sent to participants or to their next of kin annually until patient's death.
gene and SNP selection
Genes in the glutathione pathway were included, as described previously [3] . Twenty-nine genes, including isozymes and membrane-bound transporter proteins, were selected. An additional 20 genes were selected from the DNA repair pathway following a review of the literature that reported an association with treatment response or survival in lung or other cancers (supplemental Table 1 Concordance between the genomic control DNA samples was 100%. SNPs that had a minor allele frequency of <0.01 (n = 11), were not in the HardyWeinberg equilibrium (n = 5), or were monomorphic (n = 8) in this study population were excluded, resulting in 375 SNPs in the analyses.
statistical analysis descriptive analysis for study patients. Clinical characteristics of the 248 SCLC patients were first summarized by vital status and then assessed on their association with survival. Kaplan-Meier curves were obtained for each covariate, and a stepwise selection process using Cox proportional hazards regression was used to identify adjustment variables for the genetic analyses.
single-SNP assessments. For each SNP, we used a Cox regression model to assess the associations with survival following lung cancer diagnosis, both before and after adjusting for the five covariates identified above. The primary analysis tested the significance of the association between survival and the ordinal count of the number of minor alleles (zero, one, or two) carried by each individual. Secondary assessments compared heterozygotes and rare-allele homozygotes with the common-allele homozygotes to further assess the potential genetic mode of action. From both analyses, we extracted hazard ratios (HRs), 95% confidence intervals (CIs), P values, and Q values that assessed the probability that a P value might be false positive [19, 20] .
whole-gene principal components analysis. In order to assess whether different analytical approaches resulted in consistent findings, we carried out a principal components analysis (PCA) on the candidate genes. Minor allele count variables were used to identify the principal components that captured 95% of the variability in the SNPs for each gene. For the few instances where genotyping data had missing values, we imputed the mean genotype value. We identified principal components to carry out an omnibus test of significance for the association between each of the genes in the glutathione and DNA repair pathways and survival in multivariable Cox proportional hazards regression models. P values for the global tests were obtained, along with simple summaries of the outcome of the PCA.
haplotype analysis. In order to further evaluate genes whose SNPs displayed evidence for association with survival, we tested the associations between haplotypes in selected genes and survival, using tools implemented by Schaid et al. [21] i.e., age, sex, pack-years, treatment modality, and stage; they were adjusted in the final model. Supplemental Table 2 (available at Annals of Oncology online) presents summaries of the HRs, 95% CIs, and P values for these five covariates.
single-SNP analysis results
Of the 375 SNPs that were assessed for association with survival, 21 (11 genes) had P values for trend test of <0.05, after adjusting for five covariates. Fifteen of the SNPs were from the glutathione pathway and six were from the DNA repair pathway ( Table 2 ). The top three SNPs (rs11597282, rs2025096, and rs7265992) had Q values <0.25, indicating a 1 : 3 odds of being false-positive results. Two of the SNPs were in the GSS gene (rs2025096 and rs7265992) and one was in ABCC2 (rs11597282).
gene-based analysis results
Using whole-gene PCAs, 3 of the 49 genes were significantly associated with survival and had adjusted P values of <0.05;
these genes were the same ones that harbored SNPs with small P values, GSS, ABCC2, and XRCC1, with adjusted P values of 0.002, 0.04, and 0.03, respectively.
haplotype analyses
Of the three genes significant via PCAs, two were significantly associated with survival in the haplotype analyses: ABCC2 (P = 0.002) and XRCC1 (0.015). The third, GSS, had a global P value of 0.095. Four haplotypes in ABCC2 were associated with a lower risk of death (Table 3 discussion SCLC is relatively homogeneous and almost all patients are treated with chemotherapy and/or radiation, yet outcomes vary from one individual to another. The homogeneity of the disease, coupled with the heterogeneity of the outcome, provides a unique opportunity to assess the effects of genomic variations on chemotherapy-and/or radiation-induced outcomes. In this study, a systematic approach was taken to genotype all genes in the glutathione pathway and common genes in the DNA repair pathway using 375 tag SNPs (49 genes). The purpose was to test whether the genes in these pathways play any role and measure their magnitude, if any, in overall survival of SCLC after treatment. Our results indeed showed significant effects of several tested genes, particularly GSS, ABCC2, and XRCC1. Glutathione synthetase (GSS) participates in the second step of glutathione biosynthesis. Among the seven SNPs tested in this study, five showed significant association with patient survival in single-SNP analysis: rs7265992 and rs6060127 were associated with increased risk of death, while rs2025096, rs2236270, and rs2273684 were associated with reduced risk (Figure 1) . Mutations of the GSS gene cause GSS deficiency and various medical conditions, such as hemolytic anemia and 5-oxoprolinuria. However, associations between polymorphic variants in the GSS gene and lung cancer survival have not been reported to the best of our knowledge. All seven tag SNPs are intronic and their functional significance is not yet understood. Varied activities of this gene, modulated by polymorphic variation, likely impact the quantity of glutathione within a cell, which can affect the efficacy of the chemotherapy agents and patients' survival [3] .
ABCC2 (or MRP2) is a member of the multidrug resistance protein family that carries out a similar function of transporting glutathione conjugates across the cell membrane. Single-SNP variation in the ABCC2 gene was found to be associated with toxicity induced by chemotherapy agents [22] , better tumor response to chemotherapy, and longer progression-free survival for NSCLC (224TT and 3972TT) [23] . Among the 11 tag SNPs studied from the ABCC2 gene, rs11597282 ( Figure 2 ) was found to be significantly associated XRCC1 is one of the most common genes studied in the DNA base excision repair pathway. A nonsynonymous variation at amino acid position Arg399Gln (rs25487) has been linked with overall survival for both NSCLC [15, 24, 25] and SCLC (a 45-case study) patients treated with platinum-based chemotherapy [25] . Specifically, the minor allele variant, Arg/ Gln or Gln/Gln, was found to be negatively associated with patient survival in stage III and IV NSCLC after platinum-based treatment. Two copies of the variant allele increase the HR significantly (HR 2.88; 95% CI 1.36-6.10) [24] . However, this effect was found in the opposite direction in other studies, i.e., patients with the XRCC1399 Gln/Gln variant had longer survival than those with the wild-type Arg/Arg [15, 25] . Among the five SNPs in our SCLC data, rs100158 is correlated with improved survival, and rs2854510 is associated with decreased survival. Both SNPs are intronic and are more likely to be the surrogates of other functional variations in the same region with high linkage disequilibrium (supplemental Figure 1 , available at Annals of Oncology online). The XRCC1 protein interacts with other enzymes to participate in DNA base excision repair caused by ionizing radiation or alkylating agents. Existing laboratory and clinical evidence supports that tumors with enhanced NER have an intrinsic resistance to radiotherapy and chemotherapy, leading to continued tumor growth and metastasis [26] [27] [28] [29] [30] .
In this study, we did not observe any significant association for the genes commonly reported in other lung cancer studies, such as GSTP1, ERCC1, and ERCC2 [11, 12, 16, 30] . This may be related to varied responses of different cell types to radiation and/or chemotherapy because most results in the literature were obtained from NSCLC. The markers reported in the literature might not be covered by the tag SNPs from our study. Additionally, studies on SCLC have been very challenging as there is a very short window for patient recruitment and blood sample collection. Two hundred and forty-eight cases in this study were the result of a painstaking recruitment effort of >10 years. Even though it is relatively large, it may not represent the whole SCLC population and may not be big enough to 
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accommodate all haplotype combinations so risk estimates for some predictors may not be very stable.
In summary, results from our study support that genetic variations in glutathione metabolic and DNA repair pathways may be indeed associated with survival among SCLC patients. Specifically, we found genetic variation of GSS, ABCC2, and XRCC1 to be associated with overall survival of SCLC. The associations were significant not only in a single-SNP test but also at the whole-gene level and haplotype analysis. GSS and ABCC2 act on different points in the glutathione detoxification pathway; XRCC1 plays a key role in DNA base excision repair. The three may have an addictive or synergetic effect on treatment response and resistance through modulating the concentration of chemotherapy agents in the cells or their survivability after DNA damage (supplemental Figure 2 , available at Annals of Oncology online). If our results hold in additional independent validation studies particularly randomized clinical trials, targeted genotyping on these genes can be developed and used to stratify patients into good or bad responders to chemoradiation therapy so that a customized treatment plan could be developed. The refined prediction model with the genetic information could be used to project the outcomes for a patient. Because of the correlation between drug metabolic rate and toxic effects, it is also possible to adjust chemotherapy agent dosage utilizing validated genetic information. 
